<DOC>
	<DOCNO>NCT00736879</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-512148 ( Dapagliflozin ) help reduce blood sugar level subject Type 2 Diabetes well control diet exercise alone . The safety treatment also study</brief_summary>
	<brief_title>Safety Efficacy Dapagliflozin Monotherapy Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female , ≥18 ≤77 year old , type 2 diabetes mellitus Subjects must central laboratory prerandomization A1C ≥7.0 ≤ 10.0 % Cpeptide ≥ 1.0 ng/mL ( 0.34 nmol/L ) Body Mass Index ≤ 45 kg/m² Must able perform self monitor blood glucose aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3* upper limit normal ( ULN ) Serum Total bilirubin &gt; 2 mg/dL ( 34.2 µmol/L ) Creatinine kinase &gt; 3* ULN Serum creatinine ≥1.50 mg/dL ( 133 µmol/L ) male subject , ≥1.40 mg/dL ( 124 µmol/L ) female subject Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>